Form 8-K - Current report:
SEC Accession No. 0001625297-26-000008
Filing Date
2026-03-12
Accepted
2026-03-12 07:01:05
Documents
14
Period of Report
2026-03-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K indv-20260312.htm   iXBRL 8-K 27540
2 EX-99.1 a991ignitelaunchpr.htm EX-99.1 14528
6 image_0.jpg GRAPHIC 17990
  Complete submission text file 0001625297-26-000008.txt   189584

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT indv-20260312.xsd EX-101.SCH 1773
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT indv-20260312_lab.xml EX-101.LAB 22486
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT indv-20260312_pre.xml EX-101.PRE 13028
16 EXTRACTED XBRL INSTANCE DOCUMENT indv-20260312_htm.xml XML 3141
Mailing Address 10710 MIDLOTHIAN TURNPIKE SUITE 125 NORTH CHESTERFIELD VA 23235
Business Address 10710 MIDLOTHIAN TURNPIKE SUITE 125 NORTH CHESTERFIELD VA 23235 804-379-1090
Indivior Pharmaceuticals, Inc. (Filer) CIK: 0001625297 (see all company filings)

EIN.: 412520873 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37835 | Film No.: 26745603
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)